ID   FIG4_HUMAN              Reviewed;         907 AA.
AC   Q92562; Q53H49; Q5TCS6;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1997, sequence version 1.
DT   28-JUN-2023, entry version 174.
DE   RecName: Full=Polyphosphoinositide phosphatase {ECO:0000305};
DE            EC=3.1.3.- {ECO:0000269|PubMed:17556371, ECO:0000269|PubMed:33098764};
DE            EC=3.1.3.36 {ECO:0000269|PubMed:17556371};
DE            EC=3.1.3.86 {ECO:0000269|PubMed:17556371};
DE   AltName: Full=Phosphatidylinositol 3,5-bisphosphate 5-phosphatase;
DE   AltName: Full=SAC domain-containing protein 3 {ECO:0000303|PubMed:17556371};
DE   AltName: Full=Serine-protein phosphatase FIG4 {ECO:0000305};
DE            EC=3.1.3.16 {ECO:0000269|PubMed:33098764};
GN   Name=FIG4 {ECO:0000312|HGNC:HGNC:16873};
GN   Synonyms=KIAA0274, SAC3 {ECO:0000303|PubMed:17556371};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=9039502; DOI=10.1093/dnares/3.5.321;
RA   Nagase T., Seki N., Ishikawa K., Ohira M., Kawarabayasi Y., Ohara O.,
RA   Tanaka A., Kotani H., Miyajima N., Nomura N.;
RT   "Prediction of the coding sequences of unidentified human genes. VI. The
RT   coding sequences of 80 new genes (KIAA0201-KIAA0280) deduced by analysis of
RT   cDNA clones from cell line KG-1 and brain.";
RL   DNA Res. 3:321-329(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ALA-654.
RC   TISSUE=Colon;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, IDENTIFICATION IN THE PI(3,5)P2 REGULATORY
RP   COMPLEX, AND MUTAGENESIS OF ASP-488.
RX   PubMed=17556371; DOI=10.1074/jbc.m611678200;
RA   Sbrissa D., Ikonomov O.C., Fu Z., Ijuin T., Gruenberg J., Takenawa T.,
RA   Shisheva A.;
RT   "Core protein machinery for mammalian phosphatidylinositol 3,5-bisphosphate
RT   synthesis and turnover that regulates the progression of endosomal
RT   transport. Novel Sac phosphatase joins the ArPIKfyve-PIKfyve complex.";
RL   J. Biol. Chem. 282:23878-23891(2007).
RN   [6]
RP   IDENTIFICATION IN THE PI(3,5)P2 REGULATORY COMPLEX.
RX   PubMed=18950639; DOI=10.1016/j.jmb.2008.10.009;
RA   Sbrissa D., Ikonomov O.C., Fenner H., Shisheva A.;
RT   "ArPIKfyve homomeric and heteromeric interactions scaffold PIKfyve and Sac3
RT   in a complex to promote PIKfyve activity and functionality.";
RL   J. Mol. Biol. 384:766-779(2008).
RN   [7] {ECO:0007744|PDB:7K1W}
RP   STRUCTURE BY ELECTRON MICROSCOPY (5.10 ANGSTROMS), IDENTIFICATION IN THE
RP   PI(3,5)P2 REGULATORY COMPLEX, FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS
RP   OF CYS-486.
RX   PubMed=33098764; DOI=10.1016/j.molcel.2020.10.003;
RA   Lees J.A., Li P., Kumar N., Weisman L.S., Reinisch K.M.;
RT   "Insights into Lysosomal PI(3,5)P2 Homeostasis from a Structural-
RT   Biochemical Analysis of the PIKfyve Lipid Kinase Complex.";
RL   Mol. Cell 80:736-743.e4(2020).
RN   [8]
RP   VARIANT CMT4J THR-41.
RX   PubMed=17572665; DOI=10.1038/nature05876;
RA   Chow C.Y., Zhang Y., Dowling J.J., Jin N., Adamska M., Shiga K.,
RA   Szigeti K., Shy M.E., Li J., Zhang X., Lupski J.R., Weisman L.S.,
RA   Meisler M.H.;
RT   "Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and
RT   patients with CMT4J.";
RL   Nature 448:68-72(2007).
RN   [9]
RP   VARIANT ALS11 TYR-53, AND VARIANTS GLY-48; GLY-388; VAL-411; CYS-647 AND
RP   THR-902.
RX   PubMed=19118816; DOI=10.1016/j.ajhg.2008.12.010;
RA   Chow C.Y., Landers J.E., Bergren S.K., Sapp P.C., Grant A.E., Jones J.M.,
RA   Everett L., Lenk G.M., McKenna-Yasek D.M., Weisman L.S., Figlewicz D.,
RA   Brown R.H., Meisler M.H.;
RT   "Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients
RT   with ALS.";
RL   Am. J. Hum. Genet. 84:85-88(2009).
RN   [10]
RP   VARIANTS CMT4J PRO-17; THR-41 AND LYS-302, AND CHARACTERIZATION OF VARIANT
RP   CMT4J LYS-302.
RX   PubMed=21705420; DOI=10.1093/brain/awr148;
RA   Nicholson G., Lenk G.M., Reddel S.W., Grant A.E., Towne C.F.,
RA   Ferguson C.J., Simpson E., Scheuerle A., Yasick M., Hoffman S., Blouin R.,
RA   Brandt C., Coppola G., Biesecker L.G., Batish S.D., Meisler M.H.;
RT   "Distinctive genetic and clinical features of CMT4J: a severe neuropathy
RT   caused by mutations in the PI(3,5)P(2) phosphatase FIG4.";
RL   Brain 134:1959-1971(2011).
RN   [11]
RP   CHARACTERIZATION OF VARIANT CMT4J THR-41.
RX   PubMed=21655088; DOI=10.1371/journal.pgen.1002104;
RA   Lenk G.M., Ferguson C.J., Chow C.Y., Jin N., Jones J.M., Grant A.E.,
RA   Zolov S.N., Winters J.J., Giger R.J., Dowling J.J., Weisman L.S.,
RA   Meisler M.H.;
RT   "Pathogenic mechanism of the FIG4 mutation responsible for Charcot-Marie-
RT   Tooth disease CMT4J.";
RL   PLoS Genet. 7:E1002104-E1002104(2011).
RN   [12]
RP   VARIANTS YVS ASP-104 AND PRO-175, AND CHARACTERIZATION OF VARIANTS YVS
RP   ASP-104 AND PRO-175.
RX   PubMed=23623387; DOI=10.1016/j.ajhg.2013.03.020;
RA   Campeau P.M., Lenk G.M., Lu J.T., Bae Y., Burrage L., Turnpenny P.,
RA   Roman Corona-Rivera J., Morandi L., Mora M., Reutter H.,
RA   Vulto-van Silfhout A.T., Faivre L., Haan E., Gibbs R.A., Meisler M.H.,
RA   Lee B.H.;
RT   "Yunis-Varon syndrome is caused by mutations in FIG4, encoding a
RT   phosphoinositide phosphatase.";
RL   Am. J. Hum. Genet. 92:781-791(2013).
RN   [13]
RP   INVOLVEMENT IN BTOP, VARIANT BTOP VAL-783, AND CHARACTERIZATION OF VARIANT
RP   BTOP VAL-783.
RX   PubMed=24598713; DOI=10.1212/wnl.0000000000000241;
RA   Baulac S., Lenk G.M., Dufresnois B., Ouled Amar Bencheikh B., Couarch P.,
RA   Renard J., Larson P.A., Ferguson C.J., Noe E., Poirier K., Hubans C.,
RA   Ferreira S., Guerrini R., Ouazzani R., El Hachimi K.H., Meisler M.H.,
RA   Leguern E.;
RT   "Role of the phosphoinositide phosphatase FIG4 gene in familial epilepsy
RT   with polymicrogyria.";
RL   Neurology 82:1068-1075(2014).
CC   -!- FUNCTION: Dual specificity phosphatase component of the PI(3,5)P2
CC       regulatory complex which regulates both the synthesis and turnover of
CC       phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2) (PubMed:17556371,
CC       PubMed:33098764). Catalyzes the dephosphorylation of
CC       phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2) to form
CC       phosphatidylinositol 3-phosphate (PubMed:33098764). Has serine-protein
CC       phosphatase activity acting on PIKfyve to stimulate its lipid kinase
CC       activity, its catalytically activity being required for maximal
CC       PI(3,5)P2 production (PubMed:33098764). In vitro, hydrolyzes all three
CC       D5-phosphorylated polyphosphoinositide and although displaying
CC       preferences for PtdIns(3,5)P2, it is capable of hydrolyzing
CC       PtdIns(3,4,5)P3 and PtdIns(4,5)P2, at least in vitro (PubMed:17556371).
CC       {ECO:0000269|PubMed:17556371, ECO:0000269|PubMed:33098764}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,5-
CC         bisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
CC         inositol-3-phosphate) + phosphate; Xref=Rhea:RHEA:32955,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57923,
CC         ChEBI:CHEBI:58088; Evidence={ECO:0000269|PubMed:17556371,
CC         ECO:0000269|PubMed:33098764};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:32956;
CC         Evidence={ECO:0000269|PubMed:17556371, ECO:0000269|PubMed:33098764};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-
CC         bisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
CC         inositol 4-phosphate) + phosphate; Xref=Rhea:RHEA:22764,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:58178,
CC         ChEBI:CHEBI:58456; EC=3.1.3.36;
CC         Evidence={ECO:0000269|PubMed:17556371};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:22765;
CC         Evidence={ECO:0000269|PubMed:17556371};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-
CC         trisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
CC         inositol-3,4-bisphosphate) + phosphate; Xref=Rhea:RHEA:25528,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57658,
CC         ChEBI:CHEBI:57836; EC=3.1.3.86;
CC         Evidence={ECO:0000269|PubMed:17556371};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:25529;
CC         Evidence={ECO:0000269|PubMed:17556371};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + O-phospho-L-seryl-[protein] = L-seryl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:20629, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15377, ChEBI:CHEBI:29999, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:83421; EC=3.1.3.16;
CC         Evidence={ECO:0000269|PubMed:33098764};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:20630;
CC         Evidence={ECO:0000269|PubMed:33098764};
CC   -!- SUBUNIT: Component of the PI(3,5)P2 regulatory complex/PAS complex, at
CC       least composed of PIKFYVE, FIG4 and VAC14. VAC14 nucleates the assembly
CC       of the complex and serves as a scaffold by pentamerizing into a star-
CC       shaped structure, which can bind a single copy each of PIKFYVE and FIG4
CC       and coordinates their activities. {ECO:0000269|PubMed:17556371,
CC       ECO:0000269|PubMed:18950639, ECO:0000269|PubMed:33098764}.
CC   -!- INTERACTION:
CC       Q92562; Q9H8Y8: GORASP2; NbExp=3; IntAct=EBI-4290773, EBI-739467;
CC       Q92562; Q08AM6: VAC14; NbExp=5; IntAct=EBI-4290773, EBI-2107455;
CC   -!- SUBCELLULAR LOCATION: Endosome membrane {ECO:0000269|PubMed:17556371}.
CC       Note=Localization requires VAC14 and PIKFYVE.
CC       {ECO:0000269|PubMed:17556371}.
CC   -!- DISEASE: Charcot-Marie-Tooth disease 4J (CMT4J) [MIM:611228]: A
CC       recessive demyelinating form of Charcot-Marie-Tooth disease, a disorder
CC       of the peripheral nervous system, characterized by progressive weakness
CC       and atrophy, initially of the peroneal muscles and later of the distal
CC       muscles of the arms. Charcot-Marie-Tooth disease is classified in two
CC       main groups on the basis of electrophysiologic properties and
CC       histopathology: primary peripheral demyelinating neuropathies
CC       (designated CMT1 when they are dominantly inherited) and primary
CC       peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are
CC       characterized by severely reduced nerve conduction velocities (less
CC       than 38 m/sec), segmental demyelination and remyelination with onion
CC       bulb formations on nerve biopsy, slowly progressive distal muscle
CC       atrophy and weakness, absent deep tendon reflexes, and hollow feet. By
CC       convention autosomal recessive forms of demyelinating Charcot-Marie-
CC       Tooth disease are designated CMT4. {ECO:0000269|PubMed:17572665,
CC       ECO:0000269|PubMed:21655088, ECO:0000269|PubMed:21705420}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Amyotrophic lateral sclerosis 11 (ALS11) [MIM:612577]: A
CC       neurodegenerative disorder affecting upper motor neurons in the brain
CC       and lower motor neurons in the brain stem and spinal cord, resulting in
CC       fatal paralysis. Sensory abnormalities are absent. The pathologic
CC       hallmarks of the disease include pallor of the corticospinal tract due
CC       to loss of motor neurons, presence of ubiquitin-positive inclusions
CC       within surviving motor neurons, and deposition of pathologic
CC       aggregates. The etiology of amyotrophic lateral sclerosis is likely to
CC       be multifactorial, involving both genetic and environmental factors.
CC       The disease is inherited in 5-10% of the cases.
CC       {ECO:0000269|PubMed:19118816}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Yunis-Varon syndrome (YVS) [MIM:216340]: A severe autosomal
CC       recessive disorder characterized by skeletal defects, including
CC       cleidocranial dysplasia and digital anomalies, and severe neurologic
CC       involvement with neuronal loss. Enlarged cytoplasmic vacuoles are found
CC       in neurons, muscle, and cartilage. The disorder is usually lethal in
CC       infancy. {ECO:0000269|PubMed:23623387}. Note=The disease is caused by
CC       variants affecting the gene represented in this entry.
CC   -!- DISEASE: Polymicrogyria, bilateral temporooccipital (BTOP)
CC       [MIM:612691]: A disease characterized by temporo-occipital
CC       polymicrogyria, psychiatric manifestations, and epilepsy.
CC       {ECO:0000269|PubMed:24598713}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA13403.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D87464; BAA13403.2; ALT_INIT; mRNA.
DR   EMBL; AK222732; BAD96452.1; -; mRNA.
DR   EMBL; AL133472; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL512303; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC041338; AAH41338.1; -; mRNA.
DR   CCDS; CCDS5078.1; -.
DR   RefSeq; NP_055660.1; NM_014845.5.
DR   PDB; 7K1W; EM; 5.10 A; F=1-907.
DR   PDBsum; 7K1W; -.
DR   AlphaFoldDB; Q92562; -.
DR   SMR; Q92562; -.
DR   BioGRID; 115225; 27.
DR   CORUM; Q92562; -.
DR   IntAct; Q92562; 5.
DR   MINT; Q92562; -.
DR   STRING; 9606.ENSP00000230124; -.
DR   DEPOD; FIG4; -.
DR   GlyGen; Q92562; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q92562; -.
DR   PhosphoSitePlus; Q92562; -.
DR   SwissPalm; Q92562; -.
DR   BioMuta; FIG4; -.
DR   DMDM; 2497367; -.
DR   EPD; Q92562; -.
DR   jPOST; Q92562; -.
DR   MassIVE; Q92562; -.
DR   MaxQB; Q92562; -.
DR   PaxDb; Q92562; -.
DR   PeptideAtlas; Q92562; -.
DR   ProteomicsDB; 75318; -.
DR   TopDownProteomics; Q92562; -.
DR   ABCD; Q92562; 1 sequenced antibody.
DR   Antibodypedia; 56156; 281 antibodies from 29 providers.
DR   DNASU; 9896; -.
DR   Ensembl; ENST00000230124.8; ENSP00000230124.4; ENSG00000112367.12.
DR   GeneID; 9896; -.
DR   KEGG; hsa:9896; -.
DR   MANE-Select; ENST00000230124.8; ENSP00000230124.4; NM_014845.6; NP_055660.1.
DR   UCSC; uc003ptt.3; human.
DR   AGR; HGNC:16873; -.
DR   CTD; 9896; -.
DR   DisGeNET; 9896; -.
DR   GeneCards; FIG4; -.
DR   HGNC; HGNC:16873; FIG4.
DR   HPA; ENSG00000112367; Low tissue specificity.
DR   MalaCards; FIG4; -.
DR   MIM; 216340; phenotype.
DR   MIM; 609390; gene.
DR   MIM; 611228; phenotype.
DR   MIM; 612577; phenotype.
DR   MIM; 612691; phenotype.
DR   neXtProt; NX_Q92562; -.
DR   OpenTargets; ENSG00000112367; -.
DR   Orphanet; 803; Amyotrophic lateral sclerosis.
DR   Orphanet; 208441; Bilateral parasagittal parieto-occipital polymicrogyria.
DR   Orphanet; 139515; Charcot-Marie-Tooth disease type 4J.
DR   Orphanet; 3472; Yunis-Varon syndrome.
DR   PharmGKB; PA162388528; -.
DR   VEuPathDB; HostDB:ENSG00000112367; -.
DR   eggNOG; KOG1888; Eukaryota.
DR   GeneTree; ENSGT00550000074943; -.
DR   HOGENOM; CLU_003016_0_3_1; -.
DR   InParanoid; Q92562; -.
DR   OrthoDB; 996872at2759; -.
DR   PhylomeDB; Q92562; -.
DR   TreeFam; TF105702; -.
DR   BioCyc; MetaCyc:HS12771-MON; -.
DR   PathwayCommons; Q92562; -.
DR   Reactome; R-HSA-1660514; Synthesis of PIPs at the Golgi membrane.
DR   Reactome; R-HSA-1660516; Synthesis of PIPs at the early endosome membrane.
DR   Reactome; R-HSA-1660517; Synthesis of PIPs at the late endosome membrane.
DR   SignaLink; Q92562; -.
DR   SIGNOR; Q92562; -.
DR   BioGRID-ORCS; 9896; 35 hits in 1174 CRISPR screens.
DR   ChiTaRS; FIG4; human.
DR   GeneWiki; Fig4; -.
DR   GenomeRNAi; 9896; -.
DR   Pharos; Q92562; Tbio.
DR   PRO; PR:Q92562; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q92562; protein.
DR   Bgee; ENSG00000112367; Expressed in middle temporal gyrus and 204 other tissues.
DR   ExpressionAtlas; Q92562; baseline and differential.
DR   Genevisible; Q92562; HS.
DR   GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0010008; C:endosome membrane; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0031902; C:late endosome membrane; TAS:Reactome.
DR   GO; GO:0005811; C:lipid droplet; IDA:HPA.
DR   GO; GO:0055037; C:recycling endosome; IEA:Ensembl.
DR   GO; GO:0034485; F:phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase activity; IEA:RHEA.
DR   GO; GO:0043813; F:phosphatidylinositol-3,5-bisphosphate 5-phosphatase activity; IBA:GO_Central.
DR   GO; GO:0004438; F:phosphatidylinositol-3-phosphate phosphatase activity; IEA:Ensembl.
DR   GO; GO:0004439; F:phosphatidylinositol-4,5-bisphosphate 5-phosphatase activity; IEA:RHEA.
DR   GO; GO:0043812; F:phosphatidylinositol-4-phosphate phosphatase activity; IEA:Ensembl.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; IEA:RHEA.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0032288; P:myelin assembly; IEA:Ensembl.
DR   GO; GO:0031642; P:negative regulation of myelination; IEA:Ensembl.
DR   GO; GO:0048666; P:neuron development; IEA:Ensembl.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0046856; P:phosphatidylinositol dephosphorylation; IBA:GO_Central.
DR   GO; GO:0043473; P:pigmentation; IEA:Ensembl.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0007033; P:vacuole organization; IEA:Ensembl.
DR   InterPro; IPR043573; Fig4-like.
DR   InterPro; IPR002013; SAC_dom.
DR   PANTHER; PTHR45738; POLYPHOSPHOINOSITIDE PHOSPHATASE; 1.
DR   PANTHER; PTHR45738:SF5; POLYPHOSPHOINOSITIDE PHOSPHATASE; 1.
DR   Pfam; PF02383; Syja_N; 1.
DR   PROSITE; PS50275; SAC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Amyotrophic lateral sclerosis; Charcot-Marie-Tooth disease;
KW   Disease variant; Endosome; Hydrolase; Membrane; Neurodegeneration;
KW   Neuropathy; Reference proteome.
FT   CHAIN           1..907
FT                   /note="Polyphosphoinositide phosphatase"
FT                   /id="PRO_0000209743"
FT   DOMAIN          154..547
FT                   /note="SAC"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00183"
FT   REGION          707..788
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   VARIANT         17
FT                   /note="L -> P (in CMT4J; dbSNP:rs587777713)"
FT                   /evidence="ECO:0000269|PubMed:21705420"
FT                   /id="VAR_071957"
FT   VARIANT         41
FT                   /note="I -> T (in CMT4J; the mutant protein is unstable;
FT                   low levels of the protein results from impaired interaction
FT                   with VAC14; dbSNP:rs121908287)"
FT                   /evidence="ECO:0000269|PubMed:17572665,
FT                   ECO:0000269|PubMed:21655088, ECO:0000269|PubMed:21705420"
FT                   /id="VAR_036974"
FT   VARIANT         48
FT                   /note="D -> G (in dbSNP:rs1296748657)"
FT                   /evidence="ECO:0000269|PubMed:19118816"
FT                   /id="VAR_054831"
FT   VARIANT         53
FT                   /note="D -> Y (in ALS11; dbSNP:rs121908290)"
FT                   /evidence="ECO:0000269|PubMed:19118816"
FT                   /id="VAR_054832"
FT   VARIANT         104
FT                   /note="G -> D (in YVS; complete loss of function mutation;
FT                   dbSNP:rs397509395)"
FT                   /evidence="ECO:0000269|PubMed:23623387"
FT                   /id="VAR_070051"
FT   VARIANT         175
FT                   /note="L -> P (in YVS; complete loss of function mutation;
FT                   dbSNP:rs397514707)"
FT                   /evidence="ECO:0000269|PubMed:23623387"
FT                   /id="VAR_070052"
FT   VARIANT         302
FT                   /note="E -> K (in CMT4J; loss of function;
FT                   dbSNP:rs587777714)"
FT                   /evidence="ECO:0000269|PubMed:21705420"
FT                   /id="VAR_071958"
FT   VARIANT         364
FT                   /note="M -> L (in dbSNP:rs2295837)"
FT                   /id="VAR_020378"
FT   VARIANT         388
FT                   /note="R -> G (in dbSNP:rs1562667776)"
FT                   /evidence="ECO:0000269|PubMed:19118816"
FT                   /id="VAR_054833"
FT   VARIANT         411
FT                   /note="I -> V (in dbSNP:rs959747660)"
FT                   /evidence="ECO:0000269|PubMed:19118816"
FT                   /id="VAR_054834"
FT   VARIANT         647
FT                   /note="Y -> C (in dbSNP:rs150301327)"
FT                   /evidence="ECO:0000269|PubMed:19118816"
FT                   /id="VAR_054835"
FT   VARIANT         654
FT                   /note="V -> A (in dbSNP:rs9885672)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_022826"
FT   VARIANT         783
FT                   /note="D -> V (in BTOP; partial loss of function;
FT                   dbSNP:rs587777716)"
FT                   /evidence="ECO:0000269|PubMed:24598713"
FT                   /id="VAR_071959"
FT   VARIANT         902
FT                   /note="I -> T (in dbSNP:rs1162967341)"
FT                   /evidence="ECO:0000269|PubMed:19118816"
FT                   /id="VAR_054836"
FT   MUTAGEN         486
FT                   /note="C->S: Loss of phosphatase activity on PIKFYVE."
FT                   /evidence="ECO:0000269|PubMed:33098764"
FT   MUTAGEN         488
FT                   /note="D->A: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:17556371"
FT   CONFLICT        310
FT                   /note="V -> A (in Ref. 2; BAD96452)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        453
FT                   /note="S -> P (in Ref. 2; BAD96452)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        598
FT                   /note="F -> S (in Ref. 2; BAD96452)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   907 AA;  103635 MW;  7B6F115C095EC332 CRC64;
     MPTAAAPIIS SVQKLVLYET RARYFLVGSN NAETKYRVLK IDRTEPKDLV IIDDRHVYTQ
     QEVRELLGRL DLGNRTKMGQ KGSSGLFRAV SAFGVVGFVR FLEGYYIVLI TKRRKMADIG
     GHAIYKVEDT NMIYIPNDSV RVTHPDEARY LRIFQNVDLS SNFYFSYSYD LSHSLQYNLT
     VLRMPLEMLK SEMTQNRQES FDIFEDEGLI TQGGSGVFGI CSEPYMKYVW NGELLDIIKS
     TVHRDWLLYI IHGFCGQSKL LIYGRPVYVT LIARRSSKFA GTRFLKRGAN CEGDVANEVE
     TEQILCDASV MSFTAGSYSS YVQVRGSVPL YWSQDISTMM PKPPITLDQA DPFAHVAALH
     FDQMFQRFGS PIIILNLVKE REKRKHERIL SEELVAAVTY LNQFLPPEHT IVYIPWDMAK
     YTKSKLCNVL DRLNVIAESV VKKTGFFVNR PDSYCSILRP DEKWNELGGC VIPTGRLQTG
     ILRTNCVDCL DRTNTAQFMV GKCALAYQLY SLGLIDKPNL QFDTDAVRLF EELYEDHGDT
     LSLQYGGSQL VHRVKTYRKI APWTQHSKDI MQTLSRYYSN AFSDADRQDS INLFLGVFHP
     TEGKPHLWEL PTDFYLHHKN TMRLLPTRRS YTYWWTPEVI KHLPLPYDEV ICAVNLKKLI
     VKKFHKYEEE IDIHNEFFRP YELSSFDDTF CLAMTSSARD FMPKTVGIDP SPFTVRKPDE
     TGKSVLGNKS NREEAVLQRK TAASAPPPPS EEAVSSSSED DSGTDREEEG SVSQRSTPVK
     MTDAGDSAKV TENVVQPMKE LYGINLSDGL SEEDFSIYSR FVQLGQSQHK QDKNSQQPCS
     RCSDGVIKLT PISAFSQDNI YEVQPPRVDR KSTEIFQAHI QASQGIMQPL GKEDSSMYRE
     YIRNRYL
//
